Skip to main content
Premium Trial:

Request an Annual Quote

Caprion, Idec Ink CellCarta Collab; Caprion Nabs $4M Equity Investment

NEW YORK, Sept. 17 - Caprion Pharmaceuticals today said it has signed an R&D deal with Idec Pharmaceuticals potentially worth $11 million.


The multi-year deal, which landed Caprion a $4 million equity investment, calls for Idec to use Caprion's CellCarta proteomics platform to identify tumor-specific cell-surface antigen targets. The drug discoverer will then use its monoclonal antibody and radioimmunotherapy technologies to develop therapeutics against those targets, the companies said.


Beside the $4 million equity investment, Caprion, based in Montreal, stands to earn up to $7 million in tech-access fees over the life of the collaboration. Neither company would specify the intended length of the deal. Certain undisclosed milestones will trigger additional payments to Caprion, the partners said.


Click here for more information.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.